Journal: Microbiology Spectrum

Article Title: Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response

doi: 10.1128/Spectrum.00733-21

Figure Lengend Snippet: Performance indicators for the 6 serological assays

Article Snippet: Parallel testing of Genscript cPass with Diasorin-TrimericS IgG and Diasorin-S1/S2 IgG had the optimum performance.

Techniques:

Journal: Microbiology Spectrum

Article Title: Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response

doi: 10.1128/Spectrum.00733-21

Figure Lengend Snippet: Optimum cutoffs based on the ROC curves and their performances ^a

Article Snippet: Parallel testing of Genscript cPass with Diasorin-TrimericS IgG and Diasorin-S1/S2 IgG had the optimum performance.

Techniques:

Journal: Microbiology Spectrum

Article Title: Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response

doi: 10.1128/Spectrum.00733-21

Figure Lengend Snippet: Scatterplot of percentage inhibition using Genscript cPass test based on results of the PRNT.

Article Snippet: Parallel testing of Genscript cPass with Diasorin-TrimericS IgG and Diasorin-S1/S2 IgG had the optimum performance.

Techniques: Inhibition

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques: Infection

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Antibody titers by timeline.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Article Snippet: ND 50 ≥ 20 , cPass sVNT , GenScript, RBD, total , 94.68% (91.51%–96.93%) , 81.32% (74.89%–86.70%) , 0.78.

Techniques:

Journal: Journal of Korean Medical Science

Article Title: Comparison of Serologic Response of Hospitalized COVID-19 Patients Using 8 Immunoassays

doi: 10.3346/jkms.2021.36.e64

Figure Lengend Snippet: Clinical sensitivities and specificities of SARS-CoV-2 antibody detection by immunoassay kits

Article Snippet: , GenScript cPass neutralization Ab , 23/24 (0.958, 0.798–0.993) , 48/53 (0.906, 0.797–0.959).

Techniques: Enzyme-linked Immunosorbent Assay, Neutralization

Journal: Journal of Korean Medical Science

Article Title: Comparison of Serologic Response of Hospitalized COVID-19 Patients Using 8 Immunoassays

doi: 10.3346/jkms.2021.36.e64

Figure Lengend Snippet: Comparison of SARS-CoV-2 antibody results by immunoassays in serial 40 samples from 15 confirmed COVID-19 patients

Article Snippet: , GenScript cPass neutralization Ab , 23/24 (0.958, 0.798–0.993) , 48/53 (0.906, 0.797–0.959).

Techniques: Enzyme-linked Immunosorbent Assay, Neutralization